-
-
公开(公告)号：KR1019900003271B1
公开(公告)日：1990-05-12
申请号：KR1019880001996
申请日：1988-02-26
Applicant: 한국화학연구원
IPC: C07D271/06
Abstract: 1,2,4-Oxadiazole derivs. of formula (I) are provided. In (I), R=C1-8 alkyl, lower haloalkyl, lower alkoxyalkyl, lower alkenyl, dialkylaminoalkyl, azido, amino, acylamino, substd. phenoxy by H or halo, phenoxymethyl or pyridine oxymethyl. (I) are useful as a herbicide.
Abstract translation: 1,2,4-恶二唑衍生物。 的式（I）。 在（I）中，R = C 1-8烷基，低级卤代烷基，低级烷氧基烷基，低级烯基，二烷基氨基烷基，叠氮基，氨基，酰氨基。 苯氧基由H或卤素，苯氧基甲基或吡啶氧甲基。 （I）可用作除草剂。
-
-
-
-
Patent Agency Ranking
公开(公告)号：KR101965348B1
公开(公告)日：2019-04-03
申请号：KR1020170080749
申请日：2017-06-26
Applicant: 한국화학연구원
IPC: C07D231/56 , A61K31/416
-
公开(公告)号：KR101828997B1
公开(公告)日：2018-02-13
申请号：KR1020170116485
申请日：2017-09-12
Applicant: 한국화학연구원
CPC classification number: A61K31/40 , A61K35/13 , A61K35/17 , A61K2300/00
Abstract: 본발명은아니소마이신(Anisomycin) 및분리된 NK(Natural killer) 세포를포함하는, 암예방또는치료용약학적조성물및 이의용도에관한것이다. 아니소마이신이암세포의 NK 세포에대한감수성을증가시켜, NK 세포의암세포에대한세포독성이증가하는바, 본발명의조성물은아니소마이신과 NK 세포의병용처리에의해항암효과가크게증가하는시너지효과가나타난다.
-
公开(公告)号：KR101494280B1
公开(公告)日：2015-02-23
申请号：KR1020120156713
申请日：2012-12-28
Applicant: 한국화학연구원
IPC: C07C233/06 , A61K31/16 , A61P35/00
Abstract: 본 발명은 신규한 콜치신 유도체 또는 이의 약제학적으로 허용 가능한 염 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물에 관한 것이다.
본 발명의 신규한 콜치신 유도체는 Plk-1(Polo-like kinase)의 발현을 유의하게 감소시키고 p21 및 p53을 활성화시킴으로써 암세포의 증식을 현저히 억제함과 동시에 암세포의 사멸을 촉진하므로, 다양한 암에 대한 효율적인 치료 조성물로 유용하게 이용될 수 있다.-
公开(公告)号：KR1020140047057A
公开(公告)日：2014-04-21
申请号：KR1020140010822
申请日：2014-01-28
Applicant: 한국화학연구원
IPC: A61K31/4375 , A61K31/435 , A61P9/10 , A61P9/00
CPC classification number: A61K31/4375 , Y10S514/824
Abstract: The present invention relates to a composition for preventing or treating heperproliferative vascular disorders including arteriosclerosis or angiostenosis. A compound disclosed in the present invention can be used as an effective therapeutic composition for treating diseases such as arteriosclerosis and angiostenosis by significantly inhibiting proliferation of vascular smooth muscle cells which plays a key role in a progression of hyperproliferative vascular disorders.
Abstract translation: 本发明涉及用于预防或治疗包括动脉硬化或血管狭窄的增生性血管疾病的组合物。 本发明中公开的化合物可用作通过显着抑制血管平滑肌细胞的增殖来治疗疾病如动脉硬化和血管狭窄的有效治疗组合物，其在过度增生性血管疾病的进展中起关键作用。
-
80.发明公开
公开(公告)号：KR1020090123152A
公开(公告)日：2009-12-02
申请号：KR1020080049090
申请日：2008-05-27
Applicant: 한국화학연구원
IPC: A61K31/7034 , A61K31/122 , A61P19/10 , A61P19/00
CPC classification number: A61K31/7034 , A61K31/122
Abstract: PURPOSE: A pharmaceutical composition for promoting osteoblast containing physcion glucopyranoside or physcion is provided to promote mineralize mesenchymal stem cell and prevent and treat disease and symptom such as osteoporosis and fracture. CONSTITUTION: A pharmaceutical composition for preventing or treating bone disease contains 0.0001~50 weight% of physcion-8-O-β-D-glucopyranoside of chemical formula 1 or physcion of chemical formula 2 as an active ingredient. Bone disease includes fracture, osteoporosis, periodontal disease and bone growth failure. The physcion-8-O-β-D-glucopyranoside is administered in 1~150mg/kg per day. The physcion-8-O-β-D-glucopyranoside or physcion is isolated from Polygonum multiflorum.
Abstract translation: 目的：提供一种用于促进成骨细胞含有生物学药物的药物组合物，用于促进矿化间充质干细胞，预防和治疗骨质疏松症和骨折等疾病和症状。 构成：用于预防或治疗骨病的药物组合物含有化学式1的化学式8-O-β-D-吡喃葡萄糖苷或化学式2的化学式为0.0001-50重量％的活性成分。 骨病包括骨折，骨质疏松症，牙周病和骨生长失败。 生物-8-O-β-D-吡喃葡萄糖苷每天以1〜150mg / kg施用。 生物-8-O-β-D-吡喃葡萄糖苷或from ion从Poly is中分离出来。
-
-
-
-
-
-
-
-
-
Search Results
137
records
(took 0.022 seconds)
